|
|
Vaccine Detail
|
rCMV-TT |
| Vaccine Information |
- Vaccine Name: rCMV-TT
- Target Pathogen: Clostridium tetani
- Target Disease: Tetanus
- Vaccine Ontology ID: VO_0004718
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Vector:
- Preparation: Cytomegalovirus (CMV)-based vaccine platform (Tierney et al., 2012).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Mouse Response
- Vaccination Protocol: Mice were inoculated with a single intraperitoneal (i.p.) dose (5 × 10^6 pfu) of either MCMV/TetC or wild type (WT) MCMV (Δm157) control (Tierney et al., 2012).
- Vaccine Immune Response Type: VO_0003057
- Efficacy: Results show that the protective levels of anti-tetanus antibodies that are durable (lasting >13 months) in mice following only a single dose. This study demonstrates the ability of a 'single-dose' CMV-based vaccine strategy to induce durable protection, and supports the potential for a tetanus vaccine based on CMV to impact the incidence of tetanus in developing countries (Tierney et al., 2012).
|
| References |
Tierney et al., 2012: Tierney R, Nakai T, Parkins CJ, Caposio P, Fairweather NF, Sesardic D, Jarvis MA. A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice. Vaccine. 2012; 30(20); 3047-3052. [PubMed: 22414558].
|
|
